Načítá se...
Lurbinectedin: an FDA-approved inducer of immunogenic cell death for the treatment of small-cell lung cancer
Lurbinectedin is a DNA-binding inhibitor of transcription that potently induces immunogenic cell death (ICD). In June 2020, the Federal Drug Administration (FDA) approved lurbinectedin for the salvage treatment of small-cell lung cancer that has relapsed from platinum compound-based first-line chemo...
Uloženo v:
| Vydáno v: | Oncoimmunology |
|---|---|
| Hlavní autoři: | , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Taylor & Francis
2020
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7458590/ https://ncbi.nlm.nih.gov/pubmed/32923159 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2020.1795995 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|